Gilead-Kite Oncology demonstrate dedication to advancing research for hard-to-treat blood cancers at 26th Annual Meeting of the European Hematology Association (EHA) Primary results of pivotal ZUMA-3 trial, including pre-specified patient reported outcomes (PRO) in adult patients with relapsed/refractory acute lymph.
Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
Use of Corticosteroids Prior to Yescarta Infusion Has the Potential to Impact the BenefitRisk Profile Based on Data from a Cohort of ZUMA-1 Patients Response Rates Observed in New Analysis Remain Consistent with Pivotal Cohorts Kite, a Gilead Company today announced findings from a new analysis of the ZUMA-1 trial of Yescarta ® in adult patients with relapsed or refractory large B-cell lymphoma . Results … Use of Corticosteroids Prior to Yescarta Infusion Has the Potential to Impact the Benefit/Risk Profile Based on Data from a Cohort of ZUMA-1 Patients